GlassScriptPhysician profile
Lamia Kadir
NPI 1942366638
$2,211.87
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $484 · 2021: $728 · 2022: $564 · 2023: $106 · 2024: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $429.14 | 2020-2023 | |
| Novo Nordisk INC | $174.59 | 2020-2022 | |
| Lilly USA, LLC | $160.30 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.03 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $123.34 | 2022 | |
| Supernus Pharmaceuticals, INC. | $100.27 | 2021-2023 | Qelbree |
| Horizon Therapeutics Plc | $97.63 | 2020-2021 | |
| Glaxosmithkline, LLC. | $93.59 | 2021-2022 | |
| Gilead Sciences, INC. | $87.18 | 2019 | |
| Neos Therapeutics, LP | $87.03 | 2020-2022 | |
| Inspire Medical Systems, INC. | $80.29 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.89 | 2021 | |
| Adlon Therapeutics L.P. | $62.63 | 2021 | |
| Allergan, INC. | $61.45 | 2019-2020 | |
| Zoll Respicardia, INC. | $59.43 | 2024 | Remede System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $53.95 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $41.36 | 2021 | |
| Lupin INC. | $37.13 | 2020 | |
| Ironshore Pharmaceuticals INC. | $33.29 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $31.26 | 2019-2022 | |
| Agile Therapeutics, INC. | $31.13 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.34 | 2022 | |
| Ethicon US, LLC | $24.18 | 2019 | |
| Abbott Laboratories | $19.54 | 2022 | |
| Optos, INC. | $15.57 | 2021 | |
| Shield Therapeutics INC | $15.04 | 2022 | |
| Currax Pharmaceuticals LLC | $14.06 | 2022 | |
| Eisai INC. | $13.29 | 2021 | |
| Astellas Pharma US INC | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lamia Kadir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.